The new biosimilar medicine from Lek, a Sandoz company, strengthens the well-established Sandoz immunology portfolio in Slovenia and across Europe.
ISDO.ORG | All Right Reserved.
Biotechnology
-
-
Pharmaceuticals
Sandoz breaks ground on state-of-the-art Biosimilars Development Center in Ljubljana
by SBSandoz invests $90M in a cutting-edge 9,500 m² Biosimilars Development Center in Ljubljana, solidifying Slovenia’s position as a European biosimilars hub, with 200 experts advancing cell line development, biotechnological platforms, and drug formulations to expand global access to affordable, high-quality medicines.